Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nucana ( (NCNA) ) just unveiled an announcement.
On September 3, 2025, NuCana announced its participation in the European Society for Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21 in Berlin, Germany. The company will present data highlighting the synergy between its novel anti-cancer agent NUC-7738 and PD-1 inhibitors in renal cell cancer. This presentation underscores NuCana’s ongoing efforts to advance its clinical-stage products and strengthen its position in the oncology sector.
The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment outcomes by utilizing ProTide technology to transform traditional chemotherapy agents into more effective and safer medicines. Their pipeline includes NUC-7738 and NUC-3373, which are designed to overcome the limitations of nucleoside analogs and improve drug efficacy and tolerance.
Average Trading Volume: 1,166,061
Technical Sentiment Signal: Sell
Current Market Cap: $6.09M
Learn more about NCNA stock on TipRanks’ Stock Analysis page.